Effects and risk factors of TAS-102 in real-world patients with metastatic colorectal cancer, EROTAS-R study

ConclusionA better OS and PFS comparing TAS-102  + Bev to TAS-102 for CRC was achieved in a large number of real-world patients.
Source: International Journal of Clinical Oncology - Category: Cancer & Oncology Source Type: research